Robert P. Friedland, MD

PUBLICATIONS

PAPERS PUBLISHED IN REFEREED JOURNALS

1.      Friedland RP, Yahr MD.  Meningoencephalopathy secondary to infectious mononucleosis.  Archives of Neurology 34:186-188, 1977.

2.      Friedland RP, Whetsell W.  Clinicopathologic notes: Adrenocortical carcinoma with Cushing's syndrome, organic psychosis and aphasia, Mount Sinai Journal of Medicine 45:509-523, 1978.

3.      Friedland RP, Grant S.  Hematocrit, viscosity and cerebral blood flow.  American Heart Journal 97:404-405, 1979.

4.      Yen CK, Yano Y, Budinger TF, Friedland RP, Derenzo SE, Huesman RH, O'Brien HA.  Brain tumor evaluation using RB-82 and positron emission tomography.  Journal of Nuclear Medicine 23:532-537, 1982.

5.      Cooper JA, Nakada T, Knight RT, Friedland RP.  Autosomal dominant motor system degeneration in a black family.  Annals of Neurology 14:585-587, 1983.

6.      Friedland RP, Budinger TF, Yano Y, Huseman R, Knittel B, Derenzo, SE, Koss, B, Ober BA.  Regional cerebral metabolic alterations in Alzheimer-type dementia:  Kinetic studies with 18-fluorodeoxyglucose.  Journal of Cerebral Blood Flow and Metabolism 3, Suppl 1:S510-511, 1983.

7.      Friedland RP, Mathis CA, Budinger TF, Moyer BR.  Labeled choline and phosphorylcholine:  Body distribution and brain autoradiography.  Journal of Nuclear Medicine 24:812-815, 1983.

8.      Friedland, RP, Budinger TF, Ganz E, Yano Y, Mathis CA, Koss B, Ober BA, Huesman R, Derenzo S.  Regional cerebral metabolic alterations in dementia of the Alzheimer-type: positron emission tomography with 18-fluorodeoxyglucose.  Journal of Computer Assisted Tomography 7:590-598, 1983.

9.      Jones A, Friedland RP, Koss B, Ober BA, Stark, L.  Saccadic intrusions in Alzheimer-type dementia.  Journal of Neurology 229:189-194, 1983.

10.     Friedland RP, Yano Y, Budinger TF, Ganz E, Huesman RH, Derenzo SE, Knittel B.  Quantitative evaluation of blood brain barrier integrity in Alzheimer-type dementia:  Positron emission tomographic studies with rubidium-82.  European Neurology 22, Suppl 2:19-20, 1983.

11.     Koss E, Ober BA, Delis D, Friedland RP.  The Stroop color-word test: Indicator of dementia severity.  International Journal of Neurosciences 24:53-61, 1984.

12.     Friedland RP, Prusiner S, Jagust W, Budinger TF.  Bitemporal hypometabolism in Creutzfeldt-Jakob disease:  Positron emission tomography with 18F-2-fluorodeoxyglucose.  Journal of Computer Assisted Tomography 8:978-981, 1984.

13.     Friedland RP, Budinger TF, Brant-Zawadzki MN, Jagust WJ.  The diagnosis of Alzheimer-type dementia:  a preliminary comparison of PET and proton NMR imaging.  Journal of the American Medical Association 252:2750-2752, 1984.

14.     Friedland RP, Budinger TF, Koss E, Ober BA.  Alzheimer's disease:  anterior-posterior and lateral hemispheric alterations in cortical glucose utilization.  Neuroscience Letters 53:235-240, 1985.

15.     Ober BA, Koss E, Friedland RP, Delis DC.  Processes of verbal memory failure in Alzheimer-type dementia.  Brain and Cognition 4:90-103, 1985.

16.     Jagust WJ, Friedland RP, Budinger TF.  Positron emission tomography differentiates normal pressure hydrocephalus from Alzheimer's disease.  Journal of Neurology, Neurosurgery and Psychiatry 48:1091-1096, 1985.

17.     Koss E, Friedland RP, Ober BA, Jagust WJ. Differences in lateral hemispheric asymmetries of glucose utilization between early-and late-onset Alzheimer-type dementia.  American Journal of Psychiatry 142:638-640, 1985.

18.     Jagust WJ, Friedland RP.  Positron emission tomography in the study of Alzheimer's disease.  VA Practitioner 2:55-66, 1985.

19.     Friedland RP, Koss E, Jagust WJ.  Lateral hemispheric asymmetries of glucose use in Alzheimer's disease:  Relationships to behavior, age of onset and prognosis.  Journal of Cerebral Blood Flow and Metabolism 5, (Suppl 1):S123-124, 1985.

top

20.     Friedland RP, Jagust WJ, Budinger TF, Huesman RH, Knittel B.  Methodological factors affecting the accuracy of metabolic measurements in PET studies with (18F)-2-fluoro-2-deoxy-D-glucose (FDG).  Journal of Cerebral Blood Flow and Metabolism 5(Suppl. 1):S609-610, 1985.

21.     Ober BA, Dronkers NF, Koss E, Friedland RP, Delis DC.  Retrieval from semantic memory in Alzheimer-type dementia.  Journal of Clinical and Experimental Neuropsychology 8:75-92, 1986.

22.     Lakshminarayanan V, Friedland RP, Muller EC, Koss E, Stark L.  The vestibular-ocular reflex in Alzheimer's disease.  Neuro-ophthalmology 6:205-208, 1986.

23.     Jagust WJ, Budinger TF, Huesman RH, Friedland RP, Mazoyer BM, Knittel BL.  Methodological factors affecting PET measurements of cerebral glucose metabolism.  Journal of Nuclear Medicine 27:1358-1361, 1986.

24.     Luxenberg J, Friedland RP, Rapoport SI.  Quantitative X-ray computed tomography (CT) in dementia of the Alzheimer type (DAT).  Canadian Journal of the Neurological Sciences 13:570-572, 1986.

25.     Haxby JV, Grady CL, Friedland RP, Rapoport SI.  Neocortical metabolic abnormalities precede nonmemory cognitive impairments in early dementia of the Alzheimer type:  Longitudinal confirmation.  Journal of Neural Transmission 24:49-53, 1987.

26.     Grady C, Haxby JV, Horwitz B, Sundaram M, Berg G, Schapiro M, Friedland RP, Rapoport SI.  A longitudinal study of the early neuropsychological and cerebral metabolic changes in dementia of the Alzheimer type.  Journal of Clinical and Experimental Neuropsychology 10:576-596, 1988.

27.     Kaye JA, May C, Daly E, Atack JR, Sweeney DJ, Luxenberg JS, Kay AD, Kaufman S, Milstein S, Friedland RP, Rapoport SI.  Cerebrospinal fluid monoamine markers are decreased in dementia of the Alzheimer type with extrapyramidal features.  Neurology 38:554-557, 1988.

28.     Rainero I, May C, Kaye JA, Friedland RP, Rapoport SI.  Cerebrospinal fluid alpha melanocyte stimulating hormone in dementia of the Alzheimer type.  Neurology 38:1281-1284, 1988.

29.     Jagust WJ, Friedland RP, Budinger TF, Koss E, Ober B.  Longitudinal studies of regional cerebral glucose utilization in Alzheimer's disease.  Neurology 38:909-912, 1988.

30.     Luxenberg J, Plato CC, Fox KM, Friedland RP, Rapoport SI.  Digital and palmar dermatoglyphics in dementia of the Alzheimer's type.  Journal of Medical Genetics 30:733-740, 1988.

31.     Koss E, Weiffenbach JM, Haxby JV, Friedland RP.  Olfactory detection and identification performance in Alzheimer's disease.  Neurology 38:1228-1232, 1988.

32.     Friedland RP, Horwitz B, Koss E.  Measurement of disease progression in Alzheimer's disease.  Neurobiology of Aging 9:95-97, 1988.

33.     Luxenberg J, Swedo S, Flament MF, Friedland RP, Rapoport SI.  Neuroanatomic abnormalities in obsessive compulsive disorder detected with quantitative x-ray computed tomography.  American Journal of Psychiatry 145: 1089-1093, 1988.

34.     Friedland RP, Koss E, Haxby JV, Grady C, Luxenberg J, Schapiro MB,  Kaye J. The clinical and biological heterogeneity of Alzheimer's disease.  Annals of Internal Medicine 109:298-311, 1988.

35.     Friedland RP, Koss E, Kumar A, Gaine S, Metzler D, Haxby JV, Moore A,  Rapoport SI, Motor vehicle crashes in dementia of the Alzheimer type.  Annals of Neurology 24:782-786, 1988.

36.     Kumar A, Koss E, Metzler D, Moore A, Friedland RP.  Behavioral symptomatology in dementia of the Alzheimer type.  Alzheimer's Disease and Associated Disorders: An International Journal 2:363-365, 1988.

37.     Rainero I, Kaye JA, May C, Durso R, Katz DI, Albert ML, Wolfe N, Pinessi L, Friedland RP, Rapoport SI. Alpha-melanocyte stimulating hormone immunoreactivity is increased in cerebrospinal fluid of patients with Parkinson's disease.  Archives of Neurology 45:1224-1227, 1988.

38.     Haxby JV, Grady CL, Koss E, Horwitz B, Shapiro M, Friedland RP, Rapoport SI.  Heterogeneous anterior-posterior metabolic patterns in dementia of the Alzheimer type.  Neurology 38:1853-1863, 1988.

39.     Kaye JA, May C, Atack JR, Daly E, Sweeney DL, Beal MF, Kaufman S, Milstein S, Friedland RP, Rapoport SI.  Cerebrospinal fluid neurochemistry in the myoclonic subtype of Alzheimer's disease.  Annals of Neurology 24:647-650, 1988.

40.     Friedland RP.  Positron imaging in the dementing illnesses.  Journal of Neuropsychiatry and Clinical Neurosciences 39:309-310, 1989.

41.     Swedo SE, Schapiro MB, Grady CL, Cheslow DL, Leonard HL, Kumar A, Friedland RP, Rapoport SI, Rapoport JL.  Cerebral glucose metabolism in childhood-onset obsessive compulsive disorder.  Archives of General Psychiatry 46:518-523, 1989.

42.     Friedland RP, Jagust WJ, Huesman RH, Koss E, Knittel B, Mathis CA, Ober BA, Mazoyer BM, Budinger TF.  Regional cerebral glucose transport and utilization in Alzheimer's disease.  Neurology 39:1427-1434, 1989.

43.     Friedland RP. "Normal" pressure hydrocephalus and the saga of the treatable dementias.  Journal of the American Medical Association 262:2577-2581, 1989.

44.     Grady CL, Berg G, Carson RE, Daube-Witherspoon WE, Friedland RP, Rapoport SI. Quantitative comparison of glucose metabolic rates from two position emission tomographs.  Journal of Nuclear Medicine 30:1386-1392, 1989.

45.     Schapiro MB, Luxemberg JS, Kaye JA, Haxby JV, Friedland RP, Rapoport SI. Serial quantitative CT analysis of brain morphometrics in adult Down's Syndrome at different ages.  Neurology 39:1349-1353, 1989.

46.     Friedland RP.  Position emission tomography in dementia.  Seminars in Neurology 9:338-344, 1989.

47.     Friedland RP, May C, Dahlberg J. The viral hypothesis of Alzheimer's Disease: Absence of antibodies to lentiviruses.  Archives of Neurology 47:177-178, 1990.

48.     Ship JA, DeCarli C, Friedland RP, Baum B. Diminished submandibular salivary flow in dementia of the Alzheimer type.  Journal of Gerontology 45:M61-66, 1990.

49.     May C, Kaye JA, Atack JR, Schapiro MB, Friedland RP, Rapoport SI.  Cerebrospinal fluid production is reduced in healthy aging.  Neurology 40:500-503, 1990.

top

50.     Friedland RP, Luxenberg JS, Koss E. A quantitative study of intracranial calcification in dementia of the Alzheimer type.  International Psychogeriatrics 2:37-43, 1990.

51.     Kaye JA, Grady CL, Haxby JV, Moore A, Friedland RP. Plasticity in the aging brain: Reversibility of anatomic, metabolic and cognitive deficits in normal pressure hydrocephalus following shunt surgery.  Archives of Neurology 47:1336-1341, 1990.

52.     Schapiro MB, Grady CL, Kumar A, Herscovitch P, Haxby JV, Moore AM, White B, Friedland RP, Rapoport SI. Regional cerebral glucose metabolism is normal in young adults with Down Syndrome.  Journal of Cerebral Blood Flow and Metabolism 10:199-206, 1990.

53.     May C, Haber M, Young SH, Tomai TP, Csako G, Friedland RP. Osmoregulation in Alzheimer's Disease.  Dementia 1:90-94, 1990.

54.     Haxby JV, Grady CL, Koss E, Horwitz B, Heston L, Schapiro M, Friedland RP, Rapoport SI. Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. Archives of Neurology 47:753-760, 1990.

55.     Schapiro MB, Kumar A, White B, Fox D, Grady CL, Haxby JV, Friedland RP, Rapoport SI.  Dementia without mental retardation in mosaic translocation Down Syndrome.  Brain Dysfunction 3:165-174, 1990.

56.     Kumar A, Schapiro MB, Haxby JV, Grady CL, Friedland RP.  Cerebral metabolic and cognitive studies in dementia with frontal lobe behavioral features.  Journal of Psychiatric Research 24(2):97-109, 1990.

57.     Kumar A, Schapiro MB, Grady CL, Haxby JV, Wagner E, Salerno JA, Friedland RP, Rapoport SI. High resolution studies of cerebral glucose metabolism in Alzheimer's disease.  Neuropsychopharmacology 4:35-46, 1991.

58.     Friedland RP, Iadecola C. Roy and Sherrington (1890): A centennial re-examination of "On the regulation of the blood-supply of the brain".  Neurology 41:10-14, 1991. (Recipient of Lawrence McHenry Award, American Academy of Neurology, 1990)

59.     Koss E, Haxby JV, DeCarli C, Schapiro MB, Friedland RP, Rapoport SI. Patterns of performance preservation and loss in healthy aging.  Developmental Neuropsychology 7:99-113, 1991.

60.     Ober BA, Jagust WJ, Koss E, Delis DC, Friedland RP. Visuoconstructive performance and regional cerebral glucose metabolism in Alzheimer's disease.  Journal of Clinical and Experimental Neuropsychology 13:752-772, 1991.

61.     DeCarli C, Fugate L, Falloon J, Eddy J, Katz D, Friedland R, Rapoport S, Brouwers P, Pizzo P.  Brain growth and cognitive improvement in children with HIV-induced encephalopathy after six months of continuous infusion AZT therapy.  Journal of the Acquired Immune Deficiency Syndrome 4:585-592, 1991.

62.     Godec MS, Asher DM, Masters CL, Kozachuk WE, Friedland RP, Gibbs CJ, Gajdusek DC, Rapoport SI, Schapiro MB.  Evidence against the transmissibility of Alzheimer's Disease.  Neurology 41:1320, 1991.

63.     Majocha RE, Reno JM, Friedland RP, Van Haight C, Lyle LR, Marotta CA.  Development of a monoclonal antibody specific for ß/A4 Amyloid in Alzheimer's disease brain for application to in vivo imaging of amyloid angiopathy Journal of Nuclear Medicine 33:2184-2189, 1992.

64.     Friedland RP.  Alzheimer's disease:  Clinical features and differential diagnosis Neurology 43 (suppl 4):S45-S51, 1993.

65.     Friedland RP, Koss E, Lerner A, Hedera P, Jagust WJ, Ellis W, Dronkers N, Ober A.  Functional imaging, the frontal lobes, and dementia.  Dementia 4:192-203, 1993.  (Abstracted in NeuroCase 4:8, 1998)

66.     Lerner A, Friedland RP, Whitehouse PJ.  Editorial:  Role of biological markers of Alzheimer's Disease.  Alzheimer's Disease:  An International Journal 6:197-200, 1993.

67.     Friedland RP, Lerner AJ, Hedera P, Brass EP, Encephalopathy associated with bismuth subgallate therapy.  Clinical Neuropharmacology 16:173-176, 1993.

68.     Drachman DA, Swearer JM, Barnes HJ, Woodward BM, Peterson KE, Moonis M, Weintraub S, Morecroft K, Guinessey J, Acar D, Sandson T, Blass J, Nolan K, Ryan B, Morris JC, Ball LA, Friedland RP, Martin R, DeKosky ST, FuQua-Whitley D, Lineman DA, Castle J.  Driving and Alzheimer's Disease:  The risk of crashes.  Neurology 43:2448-2456, 1993.

69.     Lai S, Hopkins AL, Haacke EM, Li D, Wasserman BA, Buckley P, Friedman L, Meltzer H, Hedera P, Friedland RP.  Identification of vascular structures as a major source of signal contrast in high resolution 2D and 3D functional activation imaging of the motor cortex at 1.5T:  Preliminary results.  Magnetic Resonance in Medicine 30:387-392, 1993.

70.     Hedera P, Friedland RP.  Duane's syndrome with giant aneurysm of the vertebral basilar arterial junction.  Journal of Clinical Neuro-ophthalmology 13:271-274, 1993.

71.     Friedland RP.  Editorial:  Epidemiology, education, and the ecology of Alzheimer's disease.  Neurology 43:246-249, 1993 (published also in Portuguese in : Cadernos IPUB Envelhecimento e Saude Mental, Ed. By A. Leibing, Instituto de Psiquiatria, UFRJ, No. 10, 1999, pp. 165-174.

72.     Friedland RP.  Epidemiology and the multiple determinants of Alzheimer's disease.  Neurobiology of Aging 15:239-241, 1994.

73.     Friedland RP, Majocha RE, Reno JM, Lyle LR, Marotta CA.  Development of an anti-Aß monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease.  Molecular Neurobiology 9:107-113, 1994.

74.     Lerner AJ, Koss E, Patterson MB, Hedera P, Ownby RL, Friedland RP, Whitehouse PJ.  Concomitants of visual hallucinations in Alzheimer's disease.  Neurology 44:523-527, 1994.

75.     Hedera P, Cohen ML, Lerner AJ, Friedland RP.  Dementia preceding motor symptoms in Parkinson's disease:  A case study.  Neuropsychiatry, Neuropsychology and Behavioral Neurology 7:67-72, 1994.

76.     Weinstein EA, Friedland RP, Wagner EE. Denial/unawareness of impairment and symbolic behavior in Alzheimer's disease. Neuropsychiatry, Neuropsychology and Behavioral Neurology 7:176-184, 1994.

77.     Hedera P, Lai S, Haacke EM, Lerner AJ, Hopkins AL, Lewin JS, Friedland RP. Abnormal connectivity of the visual pathways in human albinos demonstrated by susceptibility sensitized magnetic resonance imaging. Neurology 44:1921-1926, 1994.

78.     Haacke EM, Hopkins A, Lai S, Buckley P, Friedman L, Meltzer H, Hedera P, Friedland RP, Klein S, Thompson L, Detterman D, Tkach J, Lewin JS.  2D and 3D high resolution gradient echo functional imaging of the brain venous contributions to signal in motor cortex studies.  NMR in Biomedicine 7:54-62, 1994.

79.     Hedera P, Lerner AJ, Castellani R, Friedland RP.  Concurrence of Alzheimer's disease, Parkinson's disease; diffuse Lewy body disease and amyotrophic lateral sclerosis.  Journal of Neurological Sciences 128:219-224, 1995.

80.     Hedera P, Wu D, Lewin JS, Miller D, Lerner AJ, Friedland RP.  Temporal patterns of uncoupling between oxidative metabolism and regional cerebral blood flow demonstrated by functional magnetic resonance imaging.  Investigative Radiology 30:625-633, 1995.

81.     Premkumar DRD, Cohen DL, Hedera P, Friedland RP, Kalaria RN. Apolipoprotein E4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease.  American Journal of Pathology 148:2083-95, 1996.

82.     Hedera P, Lai S, Lewin JS, Haacke EM, Wu D, Lerner AJ, Friedland RP.  Assessment of cerebral blood flow reserve using functional magnetic resonance imaging.  Journal of Magnetic Resonance Imaging 6:718-725, 1996.

83.     Thal LF, Carta A, Clarke WR, Ferris SH, Friedland RP, et al.  A one-year multicenter placebo-controlled study of acetyl-l-carnitine in patients with Alzheimer’s disease.  Neurology 47:705-711, 1996.

84.     Ogeng’o JA, Cohen DL, Sayi G, Matuja WB, Chande HM, Kitinya J, Kimani JK, Friedland RP, Mori H, Kalaria RN.  Cerebral amyloid ß protein deposits and other alzheimer lesions in non-demented elderly East Africans.  Brain Pathology 6:101-107, 1996.

top

85.     Salomon A, Jao S-C, Marcinowski K, Friedland RP, Zagorski M. Nicotine inhibits amyloid formation by the ß-peptide. Biochemistry 35:13568-78, 1996.

86.     Ford AB, Mefrouche Z, Friedland RP, Debanne SM.  Smoking and cognitive impairment: A population based study.  Journal of the American Geriatrics Society 44:905-909,1996.

87.     Lewin JS, Friedman L, Wu D, Miller D, Thompson L, Klein S, Wise A, Hedera P, Buckley P, Friedland RP. Cortical localization of human sustained attention: Detection with functional MR using a visual vigilance paradigm. Journal of Computer Assisted Tomography 20:695-701, 1996.

88.     Lundberg C, Johansson K, Ball K, Bjerre B, Blomqvist C, Braekhus A, Brouwer W, Bylsma F, Carr D, Englund L, Friedland RP, et al.  Dementia and driving - an attempt at consensus.  Alzheimer’s Disease and Associated Disorders 11:28-37, 1997.

89.     Lerner AJ, Hedera P, Koss E, Stuckey J, Friedland RP. Delirium in Alzheimer’s disease. Alzheimer’s Disease and Associated Disorders 11:16-20, 1997.

90.     Friedland RP. Strategies for driving cessation in Alzheimer’s disease. Alzheimer’s Disease and Associated Disorders 11:73-75, 1997.

91.     Hedera P, Friedland RP. Cerebral autosomal dominant anteriopathy with subcortical infarcts and leukoencephalopathy: Study of two American families with predominant dementia. Journal of Neurological Sciences 146:27-33, 1997.

92.     Lerner AJ, Koss E, Debanne SM, Rowland DY, Smyth KA, Friedland RP. Interactions of smoking history with estrogen replacement therapy as protective factors for Alzheimer’s disease (Letter). Lancet 349:403-404, 1997.

93.     Kalaria RN, Ogeng’o JA, Patel NB, Sayi JG, Kitinya JN, Chande HM, Matuja WB, Mtui EP, Kimani JK, Premkumar DRD, Koss E, Gatere S, Friedland RP.  Evaluation of risk factors for Alzheimer’s disease in elderly east Africans, Brain Research Bulletin 44:573-577, 1997.

94.     Sayi JG, Patel NB, Premkumar DRD, Adem A, Winblad B, Matuja WB, Mtui EP, Gatere S, Friedland RP, Koss E, Kalaria RN. Apolipoprotein E polymorphism in elderly East Africans. East African Medical Journal 74:668-670, 1997.

95.     Hedera P, Wu D, Collins S, Lewin JS, Miller D, Lerner AJ, Klein S, Friedland RP.  Sex and EEG synchronization after photic stimulation predict signal changes in the visual cortex detected on functional MR images.  American Journal of Neuroradiology, 19:853-857, 1998.

96.     Perry G, Smith MA, McCann CE, Siedlak SL, Jones P, Friedland RP. Cerebrovascular muscle atrophy is a feature of Alzheimer Disease. Brain Research 791:63-66, 1998.

97.     Muzic RF, Berridge MS, Friedland RP, Zhu N, Nelson AD.  Quanitification of specific binding of [¹¹C] nicotine in human brain using PET.  Journal of Nuclear Medicine 39:2048-2054, 1998.

98.     Friedland RP, Farrer LA, Cupples LA, Debanne SM, Lerner AJ, and the MIRAGE Study Group.  Smoking and risk of Alzheimer’s disease (letter) Lancet 352:819, 1998.

99.     Friedland RP, McMonagle J. Medical Legal Aspects of Alzheimer’s disease. Journal of the Cleveland Bar Association 70:69, 1999.

100.   Shi J, Perry G, Aliev G, Smith MA, Ashe KH, Friedland RP.  Serum amyloid P is not present in amyloid ß deposits of a transgenic animal model. NeuroReport  10:3229-3232, 1999.

101.   Shi J, Perry G, Smith MA, Friedland RP. Vascular abnormalities: The insidious pathogenesis of Alzheimer’s disease.  Neurobiology of Aging 21:357-361, 2000.

102.   Aliev G, Shi J, Perry G, Friedland RP, LaManna J. Decreased constitutive nitric oxide synthase, but increased inducible nitric oxide synthase and endothelin-1 immunoreactivity in aortic endothelial cells of Donryu rats on a cholesterol-enriched diet.  The Anatomical Record 259:1-10, 2000.

103.   Lerner AJ, Elston R, Chen C, Friedland RP. Response of the hypothalamic-pituitary-adrenal axis to lumbar puncture induced stress. Journal of Alzheimer’s Disease 2:193-198, 2000.

104.   Bowirrat A, Friedland, RP, Chapman J, Korczyn AD. Expedited publication:The very high prevalence of Alzheimer’s disease in an Arab population is not explained by high APOE e4 allele frequency. Neurology 55:731, 2000.

105.   Nunomura A, Perry G, Pappolla MA, Friedland RP, Hirai K, Chiba S, Smith MA. Neuronal oxidative stress precedes amyloid-Beta deposition in Down’s syndrome. Journal of Neuropathology and Experimental Neurology 59:1011-1017,2000.

106.   Aliev, G, Smith, MA, Turmaine, M, Neal ML, Zimina, TV, Friedland, RP, Perry, G, LaManna, JC, Burnstock, G.  Atherosclerotic lesions are associated with increased immunoreactivity for inducible nitric oxide synthase and endothelin-1 in thoracic aortic intimal cells of hyperlipidemic Watanabe rabbits. Experimental and Molecular Pathology 71, 40-54, 2000

107.   Zeng H, Shao H, Menon NK, Yang J, Salomon AR, Friedland RP,  Zagorski M. Nicotine and amyloid formation. Biological Psychiatry 49:248-257, 2001.

108.   Demissie S, Green RC,  Mucci L, Tziavas S, Martelli K, Bang K, Coons L, Bourque S, Buchillon D, Johnson K,  Smith T, Lautenschlager N,  Friedland RP, Cupples LA, Farrer LA.  Reliability of information collected by proxy in family studies of Alzheimer’s disease.  Neuroepidemiology 20:105-111, 2001.

109.   Seyidova D, Aliev G, Neal ML, Shi J, Vigano T, Hernandez A, Folco G, Soas AH, Smith MA, Perry G, LaManna JC, Friedland RP.The effect of agonists and antagonists on the morphology of non-transformed human smooth muscle cells in vitro Journal of Submicroscopic Cytology and Pathology (in press).

110.   Bowirrat A, Treves TA, Friedland RP, Korczyn AD. Prevalence of Alzheimer’s type dementia in an elderly Arab population. European Neurology 8:119-123, 2001.

111.   Petot GJ, Debanne SM, Reidel TM,. Smyth KA, Cook TB, Koss E, Lerner AJ, Friedland RP. Surrogate responders do not introduce bias in a case control study of dietary risk factors for Alzheimer’s disease. Journal of the American Dietetic Association 102:848-850, 2002.

112.   Friedland RP, Fritsch T, Smyth KA, Koss E, Lerner AJ, Chen CH, Petot GJ, Debanne SM. Patients with Alzheimer’s disease have reduced premorbid activities compared to healthy controls. Proceedings of the National Academy of Sciences (USA) 98:3440-3445, 2001.

113. Aliev, G, Seyidove, D, Neal, ML, Shi, J, Vigano, T, Hernandez, A, Folco, G., Soas, AH, Zimina, TV, Smith, MA, Perry, G, Lamanna, JC, Friedland, RP. The effect of agonists and antagonists on the morphology of non-transformed human smooth muscle cell in vitro. Journal of Submicroscopic Cytology and Pathology 33:141-149, 2001.

114.   Debanne SM, Petot GJ, Li J, Koss E, Lerner AJ, Riedel TM, Rowland DY, Smyth KA, Friedland RP. On the use of surrogate respondents for controls in a case-control study of Alzheimer’s disease. Journal of the American Geriatrics Society 49:1-5,2001.

115. Mizrahi E, Fritsch T, Smyth KA, Friedland RP, Lerner AJ. Medication use in Alzheimer’s Disease. Clinical Gerontologist (in press).

116. Aliev G, Smith MA, Zimina TV, Neal ML, Lamb BT, Nunomura A, Seyidova D, Vinters HV, LaManna JC, Perry G, Friedland RP. The role of oxidative stress in the pathophysiology of cerebrovascular lesions in Alzheimer’s’ disease.  Brain Pathology 12:21-35, 2002.

117. Fritsch T, McLendon MJ, Smyth KA, Lerner AJ, Chen CH, Petot GJ, Debanne SM, Soas A, Friedland RP. Effects of educational attainment on the clinical expression of Alzheimer’s disease: Results from a research registry. American Journal of Alzheimer’s Disease and Other Dementias

16:369-376, 2001.

118. Mizrahi E, Jacobsen DW, Friedland RP. Plasma homocysteine: A new risk for Alzheimer’s disease? Israel Medical Association Journal 4:1-4,2002.

119. Friedland RP, Petot GJ, Farrer LF. Diet and Alzheimer’s disease. Arab Journal of Psychiatry 13:10-17, 2002.

120. Shi J, Perry G, Berridge MS, Aliev G, Siedlak SL, Smith MA, La Manna JC, Friedland RP. Labeling of cerebral Ab deposits in vivo using intranasal bFGF and SAP component in mice, Journal of Nuclear Medicine 43:1044-1051, 2002. (Invited Commentary on this paper was published in the same issue: Potential for a sprecific neuroradiological diagnosis of Alzheimer’s disease, Blass JB, Journal of Nuclear Medicine 43:1051-1053, 2002).

121. Aliev G, Smith MA, Perry G, Samedov S, Seyidova D, Friedland RP, La Manna JC, Gasimov EK. The experimental model of Alzheimer’s disease and its selective pharmacological treatments. Academy of Sciences of Azerbaijan Reports 57:112-118, 2001.

122. Friedland RP, Lipid Metabolism, epidemiology and the mechanisms of Alzheimer’s disease. Annals of the New York Academy of Sciences 977:387-390, 2002

123. Bowirrat A, Friedland RP, Farrer L, Baldwin C, Korczyn A.  Genetic and environmental risk factors for Alzheimer’s disease in Israeli Arabs. Journal of Molecular Neuroscience 19: 239-245, 2002.

124. Aliev G, Seyidova D, Neal ML, Shi J, Lamb BT, Siedlak SL, Winters HV, Head E, Perry G, Lamanna JC, Friedland RP, Cotman CW.  Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels as a central target for the development of human AD and AD-like pathology in aged transgenic mice. Annals of the New York Academy of Sciences 977:45-64, 2002.

125. Aliev G, Smith MA, Seyidova D, Neal ML, Shi J, Loizidou M, Turmaine M, Friedland RP, Taylor I, Burnstock G, Perry G, Lamanna JC. Increased expression of NOS and ET-1 immunoreactivity in human colorectal metastatic liver tumours is associated with selective depression of constitutive NOS immunoreactivity in vessel endothelium. J Submicroscopic and Cytological Pathology 34:37-50, 2002  

126. Green RC, Cupples LA, Kurz A, Auerbach S, Go R, Sadovnick D, Duara R, DeCarli C, Kukull W, Chui H, Edeki T, Griffith P, Friedland RP, Bachman D, Farrer LA: Depression as a risk factor for Alzheimer’s disease: The MIRAGE study. Archives of Neurology 60:753-759,2003.

127. Petot G, Chen C, Traore F, Debanne S, Friedland RP, Interactions of apolipoprotein E genotype and dietary fat intake of healthy older persons during mid-adult life. Metabolism 52:279-281, 2003.

128. Farrer, L.A., Friedland RP, Bowirrat A, Waraska, Korczyn AD, Baldwin CT. Genetic and environmental risk factors for Alzheimer’s disease in Israeli Arabs. Journal of Molecular Neuroscience 20:207-212, 2003.

129.  Farrer, LA, Bowirrat, A, Friedland RP, Waraska, K, Korczyn, AD, Baldwin, CT.  Identification of multiple loci for Alzheimer disease in a consanguineous Israeli-Arab community. Human Molecular Genetics 12:415-422, 2003.

130. Mizrahi EH, Jacobsen DW, Debanne SM, Traore F, Lerner AJ, Friedland RP, Petot GJ. Plasma total homocysteine levels, dietary B6 and folate intake in AD and healthy aging. Journal of Nutrition, Health and Aging 7:160-165,2003.

131. Bowirrat A, Friedland RP, Korczyn AD, Vascular dementia among elderly Arabs in Wadi Ara, Journal of Neurological Sciences 203-204:73-76, 2003.

132. Friedland RP. Editorial: Fish consumption and the risk of Alzheimer’s disease: Is it time to make dietary recommendations? Archives of Neurology, 60:923-924, 2003.

133. Aliev G, Seyidova D, Lamb BT, Obrenovich ME, Siedlak SL, Vinters HV, Friedland RP, LaManna JC, Smith MA, Perry G. Mitochondria and vascular lesions as a central target for the development of Alzheimer’s disease and Alzheimer-like pathology in transgenic mice. Neurological Research 25:655-674, 2003.

134. Castellani RJ, Smith MA, Perry G, Friedland RP. Cerebral amyloid angiopathy: Major contributor or decorative response to Alzheimer’s disease pathogenesis.  Neurobiology of Aging (in press).

135. Petot G, Frieldand RP. Diet, lipids and Alzheimer’s disease. Journal of the Neurological Sciences (in press).

top

 

BOOKS AND BOOK CHAPTERS

 

1.      Weinstein EA, Friedland RP (Editors): Advances in Neurology, Volume 18: Hemi- inattention and Hemisphere Specialization, Raven Press, New York, 1977.

2.      Friedland RP, Weinstein EA.  Hemi-inattention and hemisphere specialization: Introduction and historical review. In: Advances in Neurology, Volume 18: Hemi-inattention and Hemisphere Specialization. Edited by Weinstein EA, Friedland RP, Raven Press, New York, 1977, pp. 131.

3.      Weinstein EA, Friedland RP. Behavioral disorders associated with hemi-attention. In: Advances in Neurology, Volume 18: Hemi-inattention and hemisphere specialization, Edited by Weinstein EA, Friedland RP, Raven Press, New York, 1977, pp. 51-62.

4.      Weinstein EA, Friedland RP. Glossary and concluding remarks. In: Advances in Neurology, Volume 18, Hemi-inattention and hemisphere specialization, Edited by Weinstein EA, Friedland RP, Raven Press, New York, 1977, pp. 137-147.

5.      Friedland RP. (Editor): The Selected Papers of Morris B. Bender, Raven Press, New York, 445 pages, 1983.

6.      Budinger TF, Huesman RH, Knittel B, Friedland RP, Derenzo SE. Physiological modeling of dynamic measurements of metabolism using positron emission tomography. In: The Metabolism of the Human Brain Studied with Positron Emission Tomography. Edited by T. Greitz et al, Raven Press, New York, pp. 165-183, 1985.

7.      Friedland RP, Budinger TF, Jagust WJ, Yano Y, Huesman RH, Knittel B. Positron emission tomography and the blood brain barrier in Alzheimer's disease. In: New Brain Imaging in Cerebrovascular Diseases. Cahn J. Lassen NA (Eds.), John Libbey Eurotext, Montrouge, France, 1985, pp. 85-93.

8.      Friedland RP, Budinger TF, Jagust WF, Koss E, Derenzo S, Huesman RH, Yano Y. Positron tomography and the differential diagnosis and pathophysiology of Alzheimer's disease. In: Senile Dementia of the Alzheimer Type, Traber J, Gispen WH, (Eds.), Springer-Verlag Co., Heidelberg, 1985, pp. 124-133.

9.      Friedland RP. Neurological aspects and cognitive dysfunction imaging and dementia, and Neuroanatomy of dementia. World Health Organization International Workshop on Epidemiology of Mental and Neurological Disease of the Elderly. Published in Chinese by the Beijing Medical University, Institute of Mental Health, Peoples Republic of China, pp. 4.1-4,.8 and 6.1-6.6, 1987.

10.     Schapiro MB, Luxenberg JS, Kaye JA, Haxby JV, White B, Moore A, Friedland RP, Rapoport SI. Serial quantitative computed tomography (CT) analysis of brain morphometry in adult Down syndrome at different ages. In: New Trends in Aging Research, volume 15 Edited by G. Pepeu, B. Tomlinson, GM Wischik. pp. 141-152, 1988.

11.     Friedland RP, Luxenberg JS. Neuroimaging in dementia. In: Clinical Neuroimaging, Theodore W, (ed.), New York, Alan R. Liss, Inc., pp. 139-163, 1988.

12.     Friedland RP. Metabolic brain imaging techniques in dementia of the Alzheimer type. In: classification and diagnosis of Alzheimer's disease: An international perspective. World Health Organization, Geneva. Edited by Hovaguimian T, Henderson S, Khatchaturian Z, Orley J, Hogrefe and Huber Publishers, Geneva pp. 122-134, 1989.

13.     Friedland RP. Brain imaging and cerebral metabolism. In: Handbook of Neuropsychology Vol. 4. Eds. Boller F, Grafman J, Elsevier Science Publishers, pp. 195-209, 1990.

14.     Friedland RP, Jagust WJ. Positron and single photon emission tomography in the differential diagnosis of dementia. In: Dementia and Positron Emission Tomography. Edited by Duara R, New York, Wiley-Liss Publishers, pp. 161-177, 1990.

15.     Friedland RP. The cerebral circulation and the mechanisms of Alzheimer's disease: In: Aging of the brain: Cellular and molecular aspects of brain aging and Alzheimer's disease (Taniguchi Symposium on Brain Sciences, No. 13). Eds: Nagatsu T and Hayaishi O, Japan Scientific Societies Press, Tokyo and Karger, Basel, pp. 147-159, 1990.

16.     Friedland RP. Positron emission tomography in dementia. In: Psychogeriatrics: Biomedical and Social Advances. Eds. Hasegawa K, Homma A., Amsterdam, Excerpta Medica, pp. 157-160, 1990.

17.     Whitehouse PJ, Friedland RP, Strauss ME. Neuropsychiatric aspects of degenerative dementias associated with motor dysfunction. In: Textbook of Neuropsychiatry. Edited by S. Yudofsky, American Psychiatric Press, Washington, D.C., pp. 585-604, 1992.

18.     Friedland RP. Wilcock G.  Dementia. In: Oxford Textbook of Geriatric Medicine.  Edited by J.G. Evans and T.F. Williams, Oxford University Press, Oxford, pp. 483-489, 1993.

19.     Hedera P, Friedland RP. Normal pressure hydrocephalus. In: Neurobase, Ed, S. Gilman et al, Arbor Publishing Co. Rochester, NY (electronic publishing, 1995, updated in 2003).

20.     Friedland RP. Effects of aging and Alzheimer's disease on perception, attention and cognition: Relationships to driving performance In: Aging and Driving Ed.  By K. Johannson, and C. Lundberg, Karolinska Institutet, Stockholm, pp. 93-96, 1994.

21.     McRae A, Rodgers-Johnson P, Friedland RP (Editors). Neurodegenerative Disorders: Common molecular mechanisms, Molecular and Chemical Neuropathology 28;1-3:1-306,1996.

22.     Friedland RP, Smyth K, Esteban-Santillan C, Koss E, Cole R, Lerner AJ, Strauss M, Whitehouse PJ, Petot G, Rowland DY, Debanne S.  Premorbid environmental complexity is reduced in patients with Alzheimer’s disease (AD) as compared to age and sex matched controls: Results of a Case-Control Study.  Proceedings of the Fifth International Conference on Alzheimer’s Disease and Related Disease, K. Iqbal, B. Winblad, H. Wisniewsk,i Eds. Neurobiology of Aging, John Wiley and Sons, New York, pp. 33-37, 1997.

23.     Friedland RP, Kalaria R, Berridge M, Miraldi F, Hedera P, Reno J, Lyle L, Marotta CA. Neuroimaging of vessel amyloid in Alzheimer’s disease.  In: Cerebrovascular Pathology in Alzheimer’s Disease J. De la Torre, V. Hachinski, Eds. Annals of the New York Academy of Sciences, Vol. 826:242-247,1997.

24.     Friedland RP. Wilcock G.  Dementia. In: Oxford Textbook of Geriatric Medicine.  (2nd edition) Edited by J.G. Evans and T.F. Williams, Oxford University Press, Oxford, pp. 922-932, 2000.

25.     Cohen DL, Hedera P, Premkumar DRD, Friedland RP, Kalaria RN. Amyloid-ß protein angiopathies masquerading as Alzheimer’s Disease? Cerebrovascular Pathology in Alzheimer’s Disease. J. De la Torre, V. Hachinski, Eds. Annals of the New York Academy of Sciences, Vol. 826:390-395, 1997.

26.     Korczyn AD, Kahana E, Friedland RP.  Education and dementia. In: Handbook of Aging and Mental Health Ed. by J. Lomranz, Plenum Press, New York, pp. 449-458, 1998.

27.     Friedland RP. Prospects for noninvasive imaging of brain amyloid ß in Alzheimer’s disease. Annals of the New York Academy of Sciences 903:123-128, 2000.

28.     Perry G, Nunomura A, Friedlich A, Boswell M, Brazdil L, Jones P, Rottkamp C, Zhu X, Raina A, Hirai K, Friedland RP, Shi J, Aliev G, Cash A, Russell R, Wataya T, Shimohama S, Atwood C, Smith MA. Factors controlling oxidative damage in Alzheimer disease: Metals and mitochondria. In: Free Radicals in Chemistry, Biology and Medicine, T. Yoshikawa, S. Et al, Eds., pp. 417-423, 2000.

29.     Small GW, DeLeon MJ, Foster NL, Friedland RP, O’Brein JT. Clinical and post-mortem validation studies. IN: Neuroimaging Research in Alzheimer’s Disease: Observations and Issues. Neurobiology of Aging (in press).

30.     Friedland RP, Anosognosia, Encyclopedia of the Neurological Sciences, Harcourt Press, (in press).

31.     Friedland RP, Korczyn AD, Farrer L.  Position Paper: Genetic and Environmental risk factors for Alzheimer’s disease in Arabs residing in Israel. In: Drug Discovery and Development for Alzheimer’s Disease: 2000, Springer Pub. Co., H. M. Fillit, A.W. O’Connel, Eds., pp. 13-16. 2002.

32. Friedland RP. Should dietary modifications be recommended to lower the risk of Alzheimer’s Disease. In: The Diversity of Alzheimer's Disease - Different Approaches and Contexts Ed. By A. Leibing and L. Sheinkman, Rio de Janeiro: ColecoesIPUB, pp. 25-36, 2002

33. Bowirrat A, Friedland, RP, Korczyn AD. Epidemiology of Alzheimer’s disease. In: Brain Disease: Theraputic Stategies and Repair. O. Abramsky, et al, Eds., Martin Dunitz Ltd, Pub. London, 299-312, 2002.

 

top

 

LETTERS and BOOK REVIEWS

 

1.      Friedland RP, Bodis-Wollner I. Letter to the Editor: Absence of somatosensory evoked potentials in patients with anosognosia. Neurology 27:695-697, 1977.

2.      Yahr MD, Friedland RP. Letter to the Editor: Acute neurological forms for infectious mononucleosis, Reply. Archives of Neurology 34:651, 1977.

3.      Friedland RP. Letter to the Editor: Communicating hydrocephalus. Lancet ii:1188, 1977.

4.      Friedland RP. Letter to the Editor: Hematocrit and cerebral blood flow. Lancet 1:41, 1978.

5.      Friedland RP. Book Review: Essays on Kuru, Edited by Hornabrook RW. Archives of Neurology 36:183, 1979.

6.      Friedland RP. Letter to the Editor: Transmission of Creutzfeldt-Jakob disease. Lancet 11:1198, 1979.

7.      Friedland RP, Koss B. Letter to the editor: Endocrine effects: laterality of lesions. Stroke 12:888, 1981.

8.      Friedland RP, Morris B. Bender: In Memorial. International Journal of Neurosciences 21:151, 1983.

9.      Friedland RP, Budinger TF. Positron emission tomography in Alzheimer's disease. IEEE Spectrum 21:103, 1984.

10.     Friedland RP, St. John JN. Video game palsy: distal ulnar neuropathy in a video game enthusiast. New England Journal of Medicine 311:58-59, 1984.

11.     Friedland RP, Brun A, Budinger TF. Pathological and positron emission tomographic correlations in Alzheimer's disease. Lancet i:228, 1985.

12.     Koss E, Friedland RP, Jagust WJ. Letter to the editor, reply: Early and late onset of Alzheimer-type dementia. American Journal of Psychiatry 143:272, 1986.

13.     Koss E, Friedland RP. Letter to the Editor (Reply): Differences between early and late onset Alzheimer-type dementia. Archives of Neurology 44:797-798, 1987.

14.     Koss E, Weiffenbach JM, Haxby JV, Friedland RP. Olfactory detection and recognition in Alzheimer's disease. Lancet 1:622, 1987.

15.     Friedland RP. Commentary on the NIH Consensus Conference on the Differential Diagnosis of Dementing Diseases. Alzheimer's Disease and Associated Disorders: An International Journal 2:17, 1988.

16.     Friedland RP, Koss E, Kumar A, Haxby JV. Letter to the Editor: Occurrence of motor vehicle crashes among patients with Alzheimer's disease: Reply. Annals of Neurology 24:782-786, 1988.

17.     Jagust WJ, Friedland RP, Budinger TF, Koss E, Ober BA. Letter to the Editor: Cerebral metabolism in Alzheimer's disease, reply. Neurology 39:309-310, 1989.

18.     Friedland RP. Letter to the Editor: Normal Pressure Hydrocephalus, reply. Journal of the American Medical Association 264:336, 1990.

19.     Friedland RP. Book Review: Eponymists in Medicine: Alzheimer and the Dementias. Eds G.E. Berrios and H.L. Freeman. Neurology 42:1258, 1992.

20.     Friedland RP. Book Review: Dementia, A Clinical Approach. JL Cummings and DF Benson, Neurology 42:1648, 1992.

21.     Friedland RP. Book Review. Neurodevelopment, Aging and Cognition. Kostovic I, Snezevic S, Wisniewski HMI, Spilich GJ, Neurology (in press).

22.     Friedland RP. Letter to the Editor: Julius Hallervorden. Neurology 43: 1453, 1993.

23.     Friedland RP. Book Review: Hannah's Heirs: The Quest for the Genetic Origins of Alzheimer's Disease. Neurology 44:590, 1994.

24.     Friedland RP. Book Review: Alzheimer's Disease: Advances in Clinical and Basic Research, B. Corain et al, Eds., Neurology 44:1989, 1994.

25.     Friedland RP, Hedera P. Letter to the Editor, Reply: The prevalence of treatable dementia. Neurology 45:601, 1995.

26.     Friedland RP. Book Review: Alzheimer's disease. RD Terry et al, Eds.. Dementia. A. Burns, R. Levy (editors) Neurology 45:209-210, 1995.

27.     Friedland RP. Letter to the Editor: Fluorine-18. Trends in Biochemical Sciences, 20:17, 1995.

28.     Friedland RP, McMonagle JJ. Crisis of competence: Capacity to execute wills is tenuous for victims of Alzheimer’s disease. American Bar Association Journal, 82:80, 1996.

29.     Friedland RP, Gilman S, Morris JC. Dementia in the elderly: is it Alzheimer’s? Patient Care 30,18-40, 1996.

30.     Ford A, Mefrouche Z, Friedland RP, Debanne SM. Smoking and cognitive impairment.  Letter (Reply) Journal of the American Geriatrics Society 44(8):905-9, 1996.

31.     Friedland RP. Molecular Mechanisms of Dementia, W. Wasco, RE Tanzi, Humana Press, 1977, Neurology 49:1192, 1997.

32.     Lerner A V, Friedland RP, The Evolution of Alzheimer’s disease (Book Review) The Gerontologist, 36:713-714, 1997.

33.     Debanne SM, Rowland DY, Friedland RP, Lerner A.  Smoking and Alzheimer’s disease: Reply The Lancet, 295, 1997.

34.     Friedland RP.  Neuroimaging in dementia.  Mediguide for Clinical Neurology, V1(4)1-8, 1997.  L. Delacorte Publishers, 1997. 

35.     Friedland RP and Krasner B. Managing Alzheimer’s patients, Letter to the Editor. Science 282:2194-2195, 1998.

36.     Friedland RP, Book Review: Alzheimer’s Disease: First Steps in Caring and Treatment, D. Kuhn, Hunter House Publishers, Journal of Alzheimer’s Disease 1:425.

38. Friedland RP, Kishikawa Y, Vega V. Suicide and Alzheimer’s disease. Journal of Geriatric Psychiatry 10:484-485, 2002.

39. Friedland RP, Etribi A, Korczyn AD, Fillit H. The First International Symposium on Alzheimer’s disease in the Middle East. World Neurology 16:10, 2001.

 

 

top

 

INVITED PRESENTATIONS

 

1.      Weinstein EA, Friedland RP. Behavioral disorders associated with hemi-inattention. Hemi-inattention and Hemisphere Specialization Symposium, Mount Sinai School of Medicine, New York, February 1976.

2.      Friedland RP. Cerebral blood flow in aging and dementia: A review. Workshop on non-invasive xenon cerebral blood flow applications, Cerebrovascular Clinical Research Center Workshop, Phoenix, February, 1979.

3.      Friedland RP, Budinger TF. Positron tomography and the diagnosis of Alzheimer's disease. AARP-NIA Conference on the Diagnosis of Alzheimer's Disease, Bethesda, Maryland, December, 1983.

4.      Budinger TF, Huesman RH, Knittel BC, Friedland RP, Ganz E, Derenzo SE. Modeling dynamic processes of metabolism, permeability and flow in the brain. Nobel Conference VII on the Metabolism of the Human Brain Studied with Positron Emission Tomography, Stockholm, May, 1983.

5.      Friedland RP. Eye movement abnormalities in Alzheimer's disease. Oculomotor System Society, Berkeley, California, February, 1984.

6.      Friedland RP. Positron imaging in dementia: implications for diagnosis and pathophysiology. Alzheimer's Disease: A Conference on Assessment and Treatment of Patients and Caregivers, Office of Geriatrics and Extended Care, VA Central Office, Palo Alto, June, 1984.

7.      Friedland RP. The etiology of Alzheimer's disease; recent developments. San Francisco Neurological Society, Pebble Beach, California, March, 1984.

8.      Friedland RP. Positron emission tomography and the blood brain barrier in Alzheimer's disease. Beaune Conference on Acute Cerebrovascular Diseases Pharmacology, Beaune, France, October, 1984.

9.      Friedland RP. PET in the early diagnosis of Alzheimer's disease. International Tropan-Bayer Symposium on Brain Aging, Cologne, November, 1984.

10.     Friedland RP. Regional alterations of glucose use in Alzheimer's disease.  Symposium on Biological Correlates of Cognitive Impairment in Alzheimer's Disease, European International Neuropsychological Society, Copenhagen, June 19985, Journal of Clinical and Experimental Neuropsychology 7:168, 1985 (Abstract).

11.     Friedland RP. Applications of PET to neuropsychology. Symposium on Diagnostic Imaging of the Brain, European International Neuropsychological Society, Copenhagen, June, 1985.

12.     Friedland RP. PET scanning and dementia. American Society of Neuroimaging, Tampa, Florida, February, 1985.

13.     Friedland RP, Jagust W. Alzheimer's disease and the blood-brain barrier. San Francisco Neurological Society, Reno, March, 1985.

14.     Friedland RP. Positron imaging in dementia: diagnostic and physiologic implications, Symposium on State of the Art Research on Alzheimer's Disease, American Psychological Association, Los Angeles, August, 1985.

15.     Budinger TF, Friedland RP. Brain imaging on dementia. Brooklodge Symposium, Cognitive dysfunctions: Therapeutic approaches. Upjohn Company, Kalamazoo, MI, June 6, 1985.

16.     Friedland RP. Positron tomography and physiologic imaging: Contrast to MRI. Neuroimaging Course, American Academy of Neurology, New Orleans, April, 1986.

17.     Friedland RP. Cerebral metabolism and blood flow in Alzheimer's disease and related disorders. Symposium on Consensus Development in the Diagnosis of Alzheimer's Disease. World Health Organization, Geneva, Switzerland, March, 1987.

18.     Friedland RP, Haxby J, Grady C, Koss E, Horwitz B, Schapiro MB, Kumar A, Rapoport SI. Longitudinal studies of neocortical metabolic alterations in dementia of the Alzheimer type. World Congress of Neurosciences, Budapest, August, 1987. Neuroscience 22(Suppl):S2, 1987.

19.     Friedland RP. The 2-deoxy-D-glucose method and PET methodology. World Congress of Neurosciences, Budapest, August, 1987. Neuroscience 22(Suppl):S107, 1987.

20.     Friedland RP. The diagnosis of dementia. Italian-USA Conference on Epidemiological Studies on Aging. Taormina, Sicily, November, 1987.

21.     Friedland RP. Neurological aspects and cognitive dysfunction in aging and dementia, and Neuroanatomy of dementia. World Health Organization International Workshop on Epidemiology of Mental and Neurological disorders in the Elderly, Beijing, November, 1987.

22.     Friedland RP. Imaging molecular pathology: Studies in dementing illness. Imaging brain chemistry: Principles and practice, Johns Hopkins Medical Institutions, March, 1988.

23.     Friedland RP. Brain imaging in Alzheimer's disease. The Fourth Congress of the International Psychogeriatric Association, Tokyo, September, 1989.

24.     Friedland RP. Chairperson and speaker, Symposium on Recent Advances in Neuroimaging Investigations of Dementing Illnesses. American Geriatrics Society and American Federation for Aging Research, Boston, May, 1989.

25.     Friedland RP. Chairperson and speaker, Intensive: Managing the Social Burden of Alzheimer's Disease. American Society on Aging, Washington, D.C., March, 1989.

26.     Friedland RP. The brain in Alzheimer's disease. Symposium: Breakthroughs in Gerontological Research. American Society on Aging, Washington, D.C., March, 1989.

27.     Friedland RP. The neuroanatomy of dementia. Symposium on Alzheimer's Disease Research in Japan, National Institute of Neuroscience, Tokyo, March, 1989.

28.     Friedland RP. The Aging Brain. American Society of Neuroradiology Course on Basic Sciences, Chicago, August, 1989.

29.     Friedland RP. The diagnosis and management of dementia. Summer Institute in Research on Aging, National Institute on Aging, Airlie, Virginia, July, 1989.

30.     Friedland RP. Brain metabolism in the neuro-degenerative disorders. The Role of Environmental Agents in Neurotoxicity. Environmental Health Institute Workshop, Stockbridge, May, 1990.

31.     Friedland RP. The cerebral circulation and the mechanisms Alzheimer's disease. The 13th Taniguchi International Symposium on Brain Sciences, La Jolla, CA, January, 1990.

32.     Friedland RP. Positron emission tomography and imaging in Alzheimer's disease. Symposium: Recent advances in the understanding of Alzheimer's disease. Foundation of American Societies for Experimental Biology,  Washington, DC, April, 1990.

33.     Friedland RP. Comparative drug development and therapy for Alzheimer and multi-infarct dementia: An American perspective. Japan Neuroscience Advisory Committee, Bristol-Myers Research Institute, Ltd., Tokyo, November, 1990.

34.     Friedland RP (Chairman). Symposium on Physiological Imaging Studies of Age Related Brain Disorders. International Psychogeriatric Association, Jerusalem, August 1991.

35.     Friedland RP. What is new in understanding, assessing, and treating Alzheimer's disease. Scientific Conference of the Ohio Network of Educational Consultants in the Field of Aging, Cleveland State University, April 19, 1991.

36.     Friedland RP. The Alzheimer patient: clinical picture and differential diagnosis. American Academy of Neurology Satellite Symposium: Neuroscience and the Socioeconomic Challenge of Alzheimer's disease (Chairman and Speaker) San Diego, May 1992.

37.     Friedland RP. Epidemiology and neurobiology of the multiple determinants of Alzheimer's disease. First Berkshire Neuroscience Symposium, Hancock, MA , July 1992.

38.     Friedland RP. Brain imaging in frontal lobe dementia, Second International Conference on Frontal Lobe Degeneration of Non Alzheimer Type. Lund, Sweden, September 1992.

39.     Friedland RP. Development of a monoclonal antibody for imaging ß amyloid in vivo. Progress in the diagnosis of Alzheimer's disease. National Caregiving Foundation, Rancho Mirage, CA, November 1993.

top

40.     Friedland RP, Co-Chairperson. Alzheimer's disease special interest social. Society for Neuroscience, Washington DC, November 1993.

41.     Friedland RP. Driving and behavior in Alzheimer's disease. Dementia and Driving Consensus Meeting, Swedish National Road Administration, Borlange, Sweden, September 1994.

42.     Friedland RP. Perceptual mechanisms and motor vehicle crashes in Alzheimer's Disease. Aging and Driving Symposium. Swedish Medical Society, Karolinska Institutet, Stockholm, September 1994.

43.     Friedland RP. Major nonpharmacological management issues in Alzheimer's disease. Dementia Update, American Academy of Neurology Annual Meeting , Post-graduate course, San Francisco, March, 1996.

44.     Friedland RP. Interventions to prevent driving. Driving and Dementia: Research, Practice and Policy. Washington University, St. Louis, May 1996.

45.     Friedland RP.  Driving behavior in Alzheimer’s disease.  National Criteria for Medical Evaluation for Driver Licensure Working Group, Association for the Advancement of Automotive Medicine, Washington University, St. Louis, May 1996.

46.     Friedland RP.  Diagnosis and neuroimaging of Alzheimer’s disease: Disciplinary and diagnostic issues in dementia.  12th Annual Alzheimer’s Disease Symposium, University of Tennessee Medical Center at Knoxville, May 1996.

47.     Friedland RP.  The placebo effect and Alzheimer’s disease drug studies. The Third Tel Aviv University Alzheimer’s Disease Conference, Tel Aviv, May 1996.

48.     Friedland RP.  (Plenary speaker) Denial and dementia..  Alzheimer’s Disease International, Twelfth International Conference, Jerusalem, October 1996.

49.     Friedland RP. Antibody imaging  in neurodegeneration. Cerebrovascular pathology in Alzheimer’s disease. New York Academy of Sciences, November 1996.

50.     Friedland RP. Major nonpharmacological management issues in Alzheimer's disease. Dementia Update, American Academy of Neurology Annual Meeting , Post-graduate course, San Francisco, April 1997.

51.     Friedland RP.  Neuroimaging of vessel amyloid in Alzheimer’s disease, OHOLO 41st Conference on Progress in Alzheimer’s and Parkinson’s Disease.  Eilat, Israel, May 1997.

52.     Friedland RP.  Amyloid imaging in Alzheimer’s disease, Fourth Tel Aviv University Alzheimer’s disease conference, May 1997.

53.     Friedland RP.  Cross-cultural epidemiology of dementia. International Psychogeritaric Association, Jerusalem, August 1997.

54.     Friedland RP. International issues in the epidemiology of dementia: Considerations from the perspective of natural selection. American Public Health Association. Indianapolis, November 1997.

55.     Friedland RP.  Management and Treatment of Alzheimer’s Disease(s). Thirteenth Annual Alzheimer’s Disease Symposium, University of Tennessee, Knoxville, May 1997.

56.     Friedland RP.  Evaluation of the presence of latent cytomegalovirus infection in cerebral arteries in Alzheimer’s disease. 4th Congress of the European Society for Clinical Neuropharmacology, Eilat, Israel, December 1997.

57.     Friedland RP.  Prospects for neuroimaging in early diagnosis and monitoring of therapy of Alzheimer’s disease.  Neuroimaging Workshop International Conference on Alzheimer’s Disease and Associated Disorders, Amsterdam, July 1998.

58.     Whitehouse PJ, Friedland RP.  Activities, appreciation and aging: Lesson for behavioral management.  Workshop "Aging 2000” Symposium: Behavioral approaches to the treatment of Alzheimer’s disease.  International Psychogeriatric Association, Munich, September 1998.

59.     Friedland RP. Laterality of frontotemporal lesions and behavior.  Third International Conference on Frontal Dementias, University of Lund, Sweden August 1998.

60.     Friedland RP.  Alzheimer’s disease and the 21st Century, Japan Well Aging Society, Annual meeting, Tokyo, November 1998.

61.     Friedland RP. Imaging amyloid in Alzheimer brain.  Vascular factors in Alzheimer’s Disease International Meeting, Northumberland, UK, May 1999.

62.     Friedland RP. Genetic and environmental risk factors for Alzheimer’s disease in Kenya and Israel.  Neuroscience in Developing Countries: Getting Around the Problems. Society for Neuroscience Workshop, November 1998, Los Angeles.

63.     Ogunniyi S, Friedland RP.  Epidemiology of dementia in Africa: The Nigerian experience.  World Federation of Neurology Research Group on Dementia, Johannesberg, September 1999.

64.     Friedland RP.  The very high prevalence of Alzheimer’s disease in an Arab population is not explained by apolipoprotein E 4 allele frequency. World Federation of Neurology Research Group on Dementia, Johannesberg, September 1999.

65.     Friedland RP. Biological markers for Alzheimer’ s disease. Seventh Tel Aviv University Alzheimer’s Disease Conference, Tel Aviv, June 1999.

66.     Friedland RP. Keynote speaker: Implications of evolutionary biology for our understanding of neurodegenerative disease. World Federation of Neurology Research Group on Neuroepidemiology, San Diego, May 2000.

67.     Friedland RP.  Apolipoprotein E genotype and dietary lipid interactions as Alzheimer’s disease risk factors. Eighth Tel Aviv University Alzheimer’s Disease Conference, Tel Aviv, June 2000.

68.     Friedland RP. Gene-environment interactions and the causal web of Alzheimer’s disease:Implications fordrug studies. Fifth International Conference on the Progress in Alzheimer’s Disease and Parkinson’s Disease. Kyoto, April 2001.

69.     Friedland RP. Alzheimer’s disease and diet. American Academy of Neurology,  Kickoff Presentations, Philadelphia, May 2001

70.     Friedland, RP. Genetic and environmental risk factors for Alzheimer’s disease in Arabs residing in Israel. Institute for the Study of Aging, First Annual Investigators Meeting, Tarrytown, NY, November 2000.

71.     Friedland RP, Lipid metabolism, statins and Alzheimer’ s disease (Discussant). National Lipid Education Council, Tucson, AZ, January, 2001.

72.     Friedland RP, Alzheimer’ s disease and evolution: Lessons from the old world. Thirteenth Annual Alzheimer’ s Disease Symposium, University of Tennessee, Knoxville, Gatlinburg, TN, June 2001.

73.     Friedland RP, Farrer LA, Bowirrat A, Launer LJ, Jacobsen DW, Mizrahi E, Baldwin C, Korczyn A.  High Alzheimer’s disease prevalence and low apolipoprotein E e4 allele frequency in Arabs residing in Israel.  Society of Neuroscientists of Africa, Nairobi, May 2001.

74. Friedland RP. Mental activity in midlife as a protective factor for Alzheimer’s disease, Eighth Tel Aviv University Alzheimer’s Disease Conference, Tel Aviv, June 2001.

top

75. Friedland RP. Genetic risk factors for Alzheimer’s disease in Arabs residing in Israel. Institute for the Study of Aging, Second Annual Investigators Meeting, Purchase, NY, November 2001.

76. Friedland RP. Diet and Alzheimer’s disease. Eight International Conference on Alzheimer’s Disease and Related Disorders, Stockholm, July 2002.

77. Friedland RP, Clinical factors of Alzheimer’s disease and vascular dementia. Third World Congress on Vascular factors in Alzheimer’s Disease, Kyoto, April 2002.

78. Friedland RP, Approaches for the development of early diagnosis of Alzheimer’s disease.  Third Annual Aluminum and Health Forum, Council on Aluminum and Health, Tokyo, April, 2002.

79. Friedland RP, Mental and physical activity and Alzheimer’s risk. 2002 Annual University  of California, Irvine, Research Conference, May 2002.

80. Friedland, RP, Farrer L. Genetic risk factors for Alzheimer’s disease in Arabs. Institute for the Study of Aging, Third Annual Investigators Meeting, Purchase, NY, October 2002.

81. Friedland RP. Evolutionary perspectives on diet and brain aging. Nutrition and Aging XVII: Nutritional Challenges in the Elderly, Little Rock, Arkansas, September 2002.

82. Friedland RP. Dietary and genetic interactions in Alzheimer’s disease. Nutritional Modulation of Aging and Age –Related Diseases, American Aging Association Annual Conference, Boston, June, 2003.

83. Friedland RP, Lipids Diet and Alzheimer’s disease. International Society for Vascular Behavioural and Cognitive Disorders (VAS-COG), Goteborg, August, 2003

84. Friedland RP, Update on early diagnosis of vascular dementia and progress in amyloid Beta protein imaging. International Society for Vascular Behavioural and Cognitive Disorders (VAS-COG), Goteborg, August, 2003

85. Friedland, RP, Cerebral amyloid angiopathy is not directly linked to the pathogenesis of Alzheimer’s disease. Challenging Views of Alzheimer’s Disease Round 2, Cincinnati, July 2003.

86. Friedland RP, Genetic and environmental risk factors for Alzheimer’s disease in Arabs residing in Israel. Institute for the Study of Aging, Fourth Annual Investigators Meeting, Teaneck, NJ, Sept. 2003.

87. Friedland, RP. Lipid metabolism, diet and Alzheimer’s disease. Research Institute For Brain and Blood Vessels, Akita, Japan, January, 2004.

 

top

 

ABSTRACTS AND PRESENTATIONS

 

1.      Abeliuk ON, Friedland RP, Nakada T, Remler MP. Multifocal glioblastoma involving both hemispheres, brainstem and cerebellum with familial tendency. Federation of Western Societies of Neurological Science, 1981.

2.      Budinger TF, Yen CK, Yano Y, Friedland RP, O'Brien HA: Blood brain barrier permeability and intravascular flow volume measurements using rubidium-82 and dynamic positron emission tomography. Society of Nuclear Medicine, St. Louis, June 1981. Journal of Nuclear Medicine 22:15, 1981.

3.      Budinger TF, Yen CK, Friedland RP. Blood brain barrier permeability and intravascular flow volume measurements using rubidium-82 and dynamic positron emission tomography. International Symposium on Cerebral Blood Flow and Metabolism, St. Louis, Missouri, June 19-24, 1981. Journal of Cerebral Blood Flow and Metabolism I (Supp.1):S47, 1981.

4.      Friedland RP, Budinger TF, Yen CK, Sargent T, Mathis C, Yano Y. Positron emission tomographic approaches to the study of dementia pathophysiology. International Study Group on the Pharmacology of Memory Disorders Associated with Aging, Zurich, Switzerland,  April 3-5, 1981.

5.      Friedland RP, Meibach RC. Effects of acetylcholinesterase inhibitors on 2-deoxy-D-glucose uptake in the rat brain. Society for Neuroscience, October, 1981, Los Angeles, California. Society for Neuroscience Abstracts 7:494, 1981.

6.      Friedland RP, budinger TF, Ganz E, Yano T, Mathis C, Huesman R, Knittel B, Ober BA, Koss B. Dementia pathophysiology: X-ray computed tomography and dynamic emission tomographic studies with 18-fluorodexoyglucose and rubidium-82. Society for Neuroscience, Minneapolis, Minnesota, November 1, 1982. Society for Neuroscience Abstracts 8(1):30, 1982.

7.      Friedland RP, Ganz E, Yano Y, Budinger T, Koss B, Ober BA. Positron emission tomography: A new approach to the dementias. San Francisco Neurological Society, Yosemite National Park, California, March 1982.

8.      Friedland RP, Koss B, Ober BA, Budinger TF, Ganz E, Yano Y. Neuropsychological correlates of regional cerebral metabolic alterations in Alzheimer-type dementia. International Neuropsychological Society, International Neuropsychological Society Bulletin, p. 22, September 1982.

9.      Koss B, Ober BA, Friedland RP, Budinger TF, Ganz E, Yano Y, Delis DC. Stroop interference effect in Alzheimer-type dementia: Relationships to severity of cognitive impairment and regional alterations in cerebral glucose metabolism: International Neuropsychological Society, Mexico City, February 1, 1983. International Neuropsychological Society Bulletin, p. 25, September 1982.

10.     Tompkins-Ober BA, Koss B, Friedland RP, Budinger TF, Ganz E, Delis DC. Verbal learning and memory functions in Alzheimer-type dementia. Society for Neuroscience, Minneapolis, Minnesota, November 1982. Society for Neuroscience Abstracts 8(II):629, 1982.

11.     Tompkins-Ober BA, Koss B, Friedland RP, Budinger TF, Ganz E, Yano Y, Delis DC. Verbal learning and visual recognition memory functions in Alzheimer-type dementia: Relationships to alternations in regional cerebral metabolic rates. International Neuropsychological Society, Mexico City, February 1983. International Neuropsychological Bulletin, p. 35, September 1982.

12.     Koss B, Friedland RP, Ober BA. Lateral asymmetry in cerebral metabolism: a prominent feature of Alzheimer-type dementia. International Neuropsychological Society, Houston, February 1984. International Neuropsychological Society Bulletin, p. 24, October 1983.

13.     Koss B, Jones A. Friedland RP, Ober B. Saccadic intrusions in Alzheimer-type dementia. American Psychological Association, Anaheim, August 1983.

14.     Friedland RP. The use of positron imaging in the differential diagnosis of dementia. San Francisco Neurological Society, Konocti Harbor, March 1983.

15.     Friedland RP, Budinger TF, Yano Y, Huesman R, Knittel B, Derenzo S, Koss B, Ober BA. Regional cerebral metabolic alterations in Alzheimer-type dementia: Studies with 18-Fluorodeoxyglucose. International Symposium on Cerebral Blood Flow and Metabolism, Paris, June 1983.

16.     Friedland RP, Yano Y, Budinger TF, Ganz E, Huesman RH, Derenzo SE, Knittel B. Quantitative evaluation of blood brain barrier integrity in Alzheimer-type dementia: Positron emission tomographic studies with rubidium-82. Satellite Symposium on Effects on Aging on Regulation of Cerebral Blood Flow and Metabolism, San Remo, June 1983.

17.     Ober BA, Dronkers NF, Koss B, Friedland RP, Delis DC. Retrieval from semantic memory in Alzheimer-type dementia. International Neuropsychological Society, Houston, February 1984. International Neuropsychological Society Bulletin, p. 26, October 1983.

18.     Koss E, Ober BA, Friedland RP, Jagust WJ. Cognitive deterioration in Alzheimer-type dementia is related to age and cerebral metabolic asymmetries. International Neuropsychological Society, San Diego, February 1985, International Neuropsychological Society Bulletin, p. 20, November 1984.

19.     Lakshiminarayanan V, Friedland RP, Muller E, Koss E, Stark L. Integrity of the vestibular-ocular reflex in Alzheimer's Disease. Society for Neuroscience, Los Angeles, October 1984. Society for Neuroscience Abstracts 10 (Part 2):775, 1984.

20.     Friedland RP, Prusiner SB, Jagust W, Koss E, Budinger TF. Regionally diminished glucose utilization in Creutzfeldt-Jakob Disease is similar so that in Alzheimer's disease. American Academy of Neurology, Boston, April 1984. Neurology (Supp. 1) 34:122, 1984.

21.     Dronkers NF, Ober BA, Simpson GV, Friedland RP. Neuropsychological and physioanatomical features of suspected Pick's disease. International Neuropsychological Society, San Diego, February 1985, International Neuropsychological Society Bulletin, p. 13, November 1984.

22.     Friedland RP, Budinger TF, Jagust WJ, Yano Y, Huesman RH, Knittel B, Koss E, Ober BA. Anterior-posterior and lateral hemispheric alter